Skip to main content
OpenTrials
Completed

NCT Number: NCT04645433

Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit

Effect of Favipiravir and Lopinavir-Ritonavir on Mortality in a Tertiary Center Intensive Care Unit: Single Center Experience

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Mortality COVID-19 Coronaviridae Infections Coronavirus Infections Infections Intensive Care Unit Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

SisliHamidiye Etfal Education and Training Hospital

Istanbul, 34771, Turkey (Türkiye)

About this study

Many agents have been given for treatment of COVID-19 infection. "Covid-19 Diagnosis and Treatment Guideline" by Ministry of Health was advised nationwide use of favipiravir or lopinavir-ritonavir although evidence was scarce for the nationwide use of lopinavir-ritonavir or favipiravir to treat COVID-19 at the time of publication date of detailed guideline Favipiravir is a RNA dependent RNA polymerase inhibitor and approved for treatment of influenza in Japan at 2014 The aim of the study was to compare ICU and hospital mortality in patients with favipiravir or lopinavir-ritonavir treatment and compare other laboratory parameters in patients treated with these two antiviral agents.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 Years and older

Exclusion criteria

  • patients younger than 18 years old
  • patients who have received both lopinavir-ritonavir and favipiravir sepuentially

Treatment and study plan

Primary outcomes

  1. Mortality for ICU

    Time frame: 14 days

    If the patient dies, we have reached an outcome

  2. hospital stay

    Time frame: 14 days

    If the hospital stay exceeds 14 days, we have reached an outcome

Sponsors and collaborators

Lead sponsor

Sisli Hamidiye Etfal Training and Research Hospital

Other

Registry information

Official study title

Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit: Single Center Experience

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Nov 27, 2020
Registry last updated
Nov 27, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.